Laboratory and Clinical Evaluation of DQ-2556

Haruko Matsuda, Yoshitsugu Miyazaki, Yuko Yoshitomi, Koutaro Mitsutake, Yasuhito Higashiyama, Kenichi Tanaka, Shigefumi Maesaki, Masanori Iwamoto, Hiroshi Yamada, Yasumasa Doutsu, Hironobu Koga, Shigeru Kohno, Kohei Hara, Takashi Chifu, Akira Sakamoto, Takashige Miyazaki, Kouichi Watanabe, Yoshinobu Hirai, Chikako Mochida, Kazuyuki SugawaraMitsuo Kaku

Research output: Contribution to journalArticlepeer-review

Abstract

The newly developed cephalosporin antibiotic agent, DQ-2556, was evaluated in vitro and in vivo. The results were as follows; 1. Antimicrobial activity: Minimal inhibitory concentrations (MICs) against 480 clinical isolates including 15 different species were determined and compared with those of cefotiam, ceftizoxime, ceftazidime and cefzonam. DQ-2556 showed excellent antimicrobial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus and gram-negative bacteria. The MICs of DQ-2556 were almost equal to those of the other cephalosporins or were lower. 2. DQ-2556 concentrations in serum and sputum: A patient with diffuse panbronchiolitis was given 1 g of DQ-2556 intravenously and its concentrations in serum and sputum were measured at intervals by HPLC. A peak concentration in serum was observed immediately after the infusion, and reached 69.7 μg/ml. A peak sputum level of 1.8μg/ml was observed 3~4 hours after the infusion. This suggests that DQ-2556 has rapid and good penetration into the lung. 3. Clinical efficacy and adverse reactions: Fourteen patients with respiratory tract infections were treated with DQ-2556. An overall efficacy rate was 78.6% (excellent in 1 case, good in 10, fair in 2, poor in 1). Fever and rash were observed in 1 case as an adverse reaction. With regards to abnormal laboratory findings, neutrocytophilia and elevation of LDH in 1 case, and elevation of GOT and GPT in another case were observed. All of these were mild and improved rapidly after completion of DQ-2556, indicating that DQ-2556 is a safe agent.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalChemotherapy
Volume41
Issue number1
DOIs
Publication statusPublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Laboratory and Clinical Evaluation of DQ-2556'. Together they form a unique fingerprint.

Cite this